molecules of the month


oral DPP9 inhibitor

in vitro synergy with NNRTI for HIV

from 250k cmpd phenotypic screen

ACS Chem. Biol.

Merck, Rahway, NJ

ICeD-2 chemical structure oral DPP9 inhibitor - Merck, Rahway, NJ
4 mins read

Context. ICeD-2 (Merck) is a dipeptidyl peptidase 9 (DPP9) inhibitor under development for HIV-1 infections. Despite the significant advancements in antiretroviral therapy research leading to the approval of some highly effective treatments, the cure for HIV-1 infection has been elusive. A phenotypic screen looking at compound-induced HIV-1 infected cell kill using infected healthy donor PBMCs ultimately led to the tool compound ICeD-2, which was found to inhibit DDP9, an intracellular serine protease.Notably, the compound synergized with a high concentration of the non-nucleoside reverse transcriptase inhibitor (NNRTI) efavirenz that lowered the effective concentration of ICeD-2 to a clinically relevant dose at a concentration that could not induce total inhibition of DPP9. Complete inhibition of DPP9 is undesirable due to its hypothesized…

request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.

already a member? log in: